The blood-brain barrier (BBB) plays an important role in the maintenance of the brain homeostasis, and its proper functions are warranted by the interplay between different cellular components (endothelial cells, astrocytes and pericytes). BBB dysfunctions in pathological conditions, and particularly in Alzheimer's disease, have been documented. Here, using an in vitro BBB model, the interaction between endothelial cells and astrocytes exposed to Ab1-42 was investigated. Human endothelial cells, cultured in monolayer or co-cultured with astrocytes, were exposed to Ab1-42 (2 lM for 18 h). Ab induced dysfunction of endothelial barrier, as assessed by enhanced permeability to FITC-conjugated dextran and reduced expression of claudin-5; these modifications were observed in the co-culture model, but not in endothelial cells cultured in monolayer. Similarly, Ab-induced damage at the barrier was observed when endothelial cells were challenged in the presence of conditioned medium generated by astrocytes previously exposed to Ab (ACM Ab). Endothelial barrier damages were associated with enhanced matrix metalloprotease 9 (MMP9) activity, known to mediate claudin-5 disruption. These events were not related to the direct effects played by Ab on endothelial cells, but they were rather the consequence of Ab-induced vascular endothelial growth factor (VEGF) expression in astrocytes. Indeed, when vascular endothelial growth factor expression was down-regulated in astrocytes, neither barrier properties or MMP9 expression in endothelial cells were affected after Ab exposure both in the co-culture model or in the presence of ACM Ab. These data point out the importance of astrocytes' mediation in inducing endothelial sensitivity to Ab1-42 .
The blood-brain barrier (BBB) consists of specialized endothelial cells that, together with other components of the neurovascular unit (NVU; pericytes, astrocytes and neurons), preserve the proper environment in the central nervous system (CNS), restricting the entry of potentially harmful blood-borne agents, metabolites, drugs and immune cells into the CNS. Affections at the BBB functions have been often related to CNS pathological states. The involvement of the barrier in the initiation and perpetuation of multiple sclerosis is well documented (Ortiz et al. 2014) , as well as of amyotrophic lateral sclerosis, Parkinson's disease and Huntington's disease (Capaldo and Nusrat 2009) . Recently BBB involvement in Alzheimer's disease (AD) has been proposed. The progressive and irreversible cognitive decline that characterizes the disease is the consequence of beta amyloid (Ab) accumulation and tau protein hyperphosphorylation that lead to neuronal degeneration, synaptic loss, plaque formation and gliosis. The leakage of the BBB has been often observed in patients with early AD (van de Haar et al. 2016) , and post-mortem studies show coexisting cerebrovascular affections in AD patients (de la Torre 2002; Jellinger and Attems 2005; Keller 2013 ). Recent studies support the idea that BBB involvement in AD could precede neurodegenerative events (Bell and Zlokovic 2009; Zhao et al. 2015) . The two-hit vascular hypothesis (Wang et al. 2014; Lamoke et al. 2015) proposes that endothelial dysfunction at the BBB, consequence of cerebrovascular damage, can be the first event leading to Ab overload in the CNS (second hit), thus causing neurodegeneration (Sagare et al. 2012; Brkic et al. 2015) . BBB dysfunction caused by Ab challenge may result in impaired neuronal metabolic supply and reduced Ab clearance through the barrier (Di Marco et al. 2015) , thus increasing its load in the CNS. Ab itself can affect endothelial properties. In in vitro BBB model, Ab exposure induces the expression of adhesion molecules ICAM-1 and VCAM-1 (Liu et al. 2011) , and modifies the distribution of tight junction (TJ) proteins, (Marco and Skaper 2006; Gonzalez-Velasquez et al. 2008; Nagababu et al. 2009 ). TJs are the main modulators of paracellular movement of solutes across endothelial barrier (Garcia et al. 2014) and in pathological states are considered as proper indicators of BBB structural modifications (Abbott et al. 2006; Zenaro et al. 2016) . Astrocytes affect BBB function as they release several factors able to induce the formation of TJs, enhance the expression of transporters (Cheslow and Alvarez 2016) and modulate endothelial response to inflammatory stimuli. The role that astrocytes play in neurodegenerative disorders, such as AD, is still unclear. They can certainly reduce support of neuronal activities and release chemokines and cytokines [reviewed in (Garwood et al. 2016) ] that can aggravate neuronal degeneration. Nevertheless, astrocytes can also play a protective role in models of neurodegeneration (Jo et al. 2014) . Here, using an in vitro BBB model, we explored the interaction of astrocytes with endothelial cells after Ab challenge. Human endothelial cells and astrocytes were either exposed to Ab independently or in a more physiological condition in which direct interaction between the cells was enabled. The presence of astrocytes was essential to induce endothelial response to Ab, resulting in increased barrier permeability and TJ disruption.
Materials and methods
All studies were carried out using cell lines and no institutional approval is required in this case.
Drugs and reagents
Cell culture plastics were provided by BD Falcon (Milan, Italy). Polycarbonate membrane transwell inserts, pores 3 lm, and collagen I rat tail were provided by Corning (Milan, Italy). MCDB-131 medium and fetal bovine serum (FBS) were from Invitrogen Srl (Milan, Italy). EGM-2 SingleQuotsTM was provided by Lonza, (Basel, Switzerland) . Astrocyte medium was from ScienCell Research Laboratories (Carlsbad, CA USA). Beta amyloid (Ab1-42) peptide (Innovagen, Lund, Sweden) was solubilized in dimethylsulfoxide as a 5 mM stock. For experiments, 100 lM Ab(1-42) was aggregated by overnight incubation at 4°C followed by freeze-thaw cycles to be enriched in oligomers, as previously described (Merlo and Sortino 2012) . GM6001 was from Merck (Merck Millipore, Darmstadt, Germany). The following primary antibodies were used: antirabbit Claudin-5 (1 : 200 for WB and 1 : 100 for ICC, Thermo Fisher Scientific Cat# 34-1600 RRID:AB_2533157, Milan Italy), anti-rabbit matrix metalloprotease 9 (MMP9; 1 : 800, Millipore Cat# AB19016 RRID:AB_91090), anti-rabbit MMP2 (1 : 700, SantaCruz Biotechnology, CA, USA sc-10736 RRID:AB_2250826), anti-rabbit vascular endothelial growth factor (VEGF) (1 : 400, Santa Cruz Biotechnology Cat# sc-152 RRID:AB_2212984), anti-rabbit betaactin (1 : 2500, Sigma-Aldrich St Louis, MO, USA, Cat# A2066 RRID:AB_476693), anti-mouse alpha-tubulin (1 : 5000, SigmaAldrich, Cat# T9026 RRID:AB_477593).
Cell culture TY-10 cells, an adult human brain microvascular endothelial cell line, were immortalized after transfection with plasmid expressing temperature sensitive Simian virus-40 large T-antigen (ts-SV40-LT) and the catalytic subunit of human telomerase, as previously described (Sano et al. 2010; Spampinato et al. 2015) . TY-10 cells were grown in MCDB-131 media (Sigma-Aldrich) supplemented with EGM-2 SingleQuotsTM and 20% heat-inactivated FBS. Astrocytes (hAST), a human cell line, were immortalized after transfection with the same ts-SV40-LT, plasmid as previously described (Haruki et al. 2013) , and were grown in astrocyte media containing 2% heat-inactivated FBS, astrocyte growth supplement and penicillin/streptomycin solution as provided with the Astrocyte media kit (ScienCell Research Laboratories). Both cell lines were developed at Yamaguchi University (Japan), in the labs of Dr Sano and Kanda. For experiments, both TY-10 cells and hAST were grown at 33°C until confluency was reached and then transferred at 37°C, where they exhibit growth arrest and differentiation. After 2 days of differentiation, cells were exposed to Ab 1-42 for 18 h. To achieve astrocyte conditioned medium (ACM), astrocytes were exposed to either vehicle (ACM resting) or Ab1-42, 2 lM (ACM Ab), for 6 h, then washed and incubated with fresh medium for further 18 h. This particular paradigm was chosen in order to allow exposure of astrocytes to Ab for a reasonable time to induce Ab effects before removal so that transferred ACM did not contain any Ab.
FITC-dextran permeability assay
In the monolayer model, endothelial cells were plated on collagen type-I-coated polycarbonate transwell tissue culture inserts (0.33 cm 2 inserts, 120 k/each) and regularly checked for confluency. In the co-culture model, hAST were seeded on 24 well plates (90 k/well bodies (LI-COR). Detection of specific bands was carried out using the Licor Odyssey â Infrared Imaging System (LI-COR). Band intensity was analyzed, using the image processing software "Image J" developed by NIH and in public domain.
Subcellular protein fractionation
Separation and preparation of cytoplasmic and membrane protein extracts from endothelial cells were performed, using the subcellular protein fractionation kit for cultured cells (ThermoScientific) according to the manufacturer's instruction. Extracts obtained were then processed for western blotting after protein quantification using the Bradford reagent.
Qrt-pcr
Total RNA was extracted from cell cultures using the RNeasy plus Mini Kit (Qiagen, Milan). One lg of RNA was used for cDNA synthesis, using the Superscript-VILO kit (Invitrogen) according to manufacturer's instruction. Quantitative real-time PCR was performed with Rotor Gene Q using QuantiNova SYBR Green PCR Kit (Qiagen). The melting curves obtained after each PCR amplification reaction confirmed the specificity of the 2-
The following primers were used: VEGF (F 5 0 -
(Qiagen, cat n. QT00075012). For MMP 9 and MMP 2 primers were exactly as described (Munaut et al. 2003) .
Gelatin zymography assay
Equal amount of endothelial medium in non-reducing conditions were separated in an 8% sodium dodecyl sulfate-polyacrylamide gel containing 0.1% porcine skin gelatin (300 bloom, Sigma-Aldrich, Milan, Italy). The gel was washed in renaturing buffer (2.5% Triton X-100) for 45 min at 25°C. Then it was incubated with zymography development buffer (Bio-Rad Laboratories, Milan, Italy) for 45 min at 25°C and maintained in fresh zymography development buffer for 22 h at 37°C. Finally the gel was stained with 0.25% R-250 Coomassie solution (Sigma; 30 min at 25°C) and destained in a 2 : 1 methanol:acetic acid solution (30 min at 25°C). Odyssey scanner was used to acquire digital scan of the gels. Images were subjected to densitometric analysis with the aid of the Image J processing software.
VEGF silencing
Cultured astrocytes were transfected with lipofectamine 2000 (Invitrogen) and either negative control or VEGF siRNA (1.5 pM; Santa Cruz). Incubation was carried out in Optimem medium for 6 h at 37°C, and let to recover in complete astrocyte medium for 18 h. Endothelial cells were then co-cultured with astrocytes for 24 h and co-cultures were exposed to treatment for further 18 h.
Statistical analysis
Data shown are always mean AE SEM of 3-7 independent experiments each run in triplicates or quadruplicates. Data were analyzed by Student's t-test or by one-way ANOVA followed by NewmanKeuls test for significance when three or more conditions were compared. Here p < 0.05 was taken as the criterion for statistical significance.
Results
Astrocytes influence Ab effects at endothelial level Human brain microvascular endothelial cell monolayer (TY-10 cells) was exposed to 2 lM Ab1-42 for 18 h and barrier properties were investigated. Paracellular diffusion was evaluated by the measure of endothelial permeability to 10 kDa FITC-conjugated dextran. Exposure to 2 lM Ab1-42 was not able to induce any variation in dextran diffusion at the time point examined (30 min; Fig. 1a ). Observation was prolonged at longer time points (up to 120 min), but no changes were detectable (Data S1a and b). TY-10 cells were then co-cultured with human astrocytes (hAST) and exposed to 2 lM Ab1-42 for 18 h; in this set of experiments, the amount of the dye-conjugated molecule going through the endothelial monolayer was significantly increased after 30 min of exposure to dextran (Fig. 1b) . This increase was maintained at later time points (60 and 120 min, Fig. S1c and d). The higher permeability was not consequence of cell death: Ab1-42 did not modify in fact viability of either endothelial cells or astrocytes (Data S2). Increased paracellular permeability was accompanied by modifications in the structure of TJ. The expression of claudin-5, the main constituent of TJ, was assessed after Ab1-42 challenge. When the endothelial monolayer was exposed to 2 lM Ab1-42 for 18 h no variations in the expression of claudin-5 were detected (Fig. 2a) . However, immunocytochemical analysis showed that claudin-5, which was mostly localized at the cell boundaries under resting conditions (control), was altered following Ab1-42 treatment resulting in its intracellular redistribution (Fig. 2b , indicated by asterisks). In contrast, when endothelial cells were grown in co-culture with astrocytes and exposed to 2 lM Ab1-42 for 18 h, the treatment significantly reduced the expression of claudin-5 (Fig. 2c) and the intracellular redistribution of claudin-5 was more diffuse (compare asterisks between Fig. 2b and d) . Moreover, the cell to cell junctions were loosened (white arrows in Fig. 2d ). To further verify Abinduced TJ redistribution inside the cell, subcellular protein fractionation was performed. Cytoplasmic and membrane fractions were isolated and the expression of claudin-5 was evaluated. The total amount of claudin-5 expressed in the cytoplasmic fraction was increased by Ab treatment (Fig. 2e) , while the expression of claudin-5 localized at the membrane was significantly reduced (Fig. 2f) .
Astrocyte-released soluble factors modulate Ab effects at endothelial level The reported data prompted us to investigate whether soluble factors produced by astrocytes could affect endothelial response to Ab. Astrocytes conditioned medium (ACM) was generated by cultures exposed to vehicle or Ab1-42 for 6 h, and collected after 18 h of recovery (ACM resting and ACM Ab, respectively). Endothelial exposure to either ACM resting or Ab failed to modify FITC-conjugated dextran permeability (Fig. 3a) . Endothelial cells were subsequently exposed to Ab1-42, 2 lM, in the presence of media released by either resting (ACM resting) or Ab-challenged (ACM Ab) astrocytes. In the presence of ACM resting, Ab treatment did not modify endothelial properties (Fig. 3b) , whereas ACM Ab increased endothelial sensitivity to Ab challenge (Fig. 3c) . Accordingly, the expression of claudin-5 was not affected when endothelial cells were exposed to ACM either Fig. 1 Ab1-42 affects endothelial permeability only in the presence of astrocytes. Endothelial cultures were exposed to Ab1-42 (Ab) 2 lM for 18 h. Endothelial properties were evaluated measuring FITC-conjugated dextran permeability through the monolayer, 30 min after addition of the dye (a). Endothelial cells were co-cultured with astrocytes and exposed to Ab 2 lM for 18 h before permeability assay was performed (b). Monolayer permeability is expressed as percentage of control of FITC-dextran-10 kDa fluorescent intensity, plotted on the Y-axis. Values represent mean AE SEM of 3 (a) and 4 (b) independent experiments. *p < 0.05 versus control. Significance was assessed by Student's t test.
from resting or Ab challenged astrocytes (Fig. 3d) , but when endothelial cells were challenged with Ab in the presence of ACM Ab, the expression of claudin-5 was significantly reduced (Fig. 3e) . The cellular localization of the protein was as well modified in these conditions: Ab treatment induced claudin-5 translocation from the cell boundaries, reducing cell to cell contact (arrows in Fig. 3f) ; the increased localization of the protein at the cytosolic fraction (Fig. 3g) was confirmed by western blot analysis that showed also a reduction in membrane-localized claudin-5 (Fig. 3h) after Ab challenge.
Ab induces the expression of VEGF in astrocytes
Among all the factors that astrocytes release upon Ab1-42 activation, attention was focused on VEGF. After exposure of astrocytes to 2 lM Ab1-42, both VEGF mRNA and protein levels were increased. The mRNA peak was significantly reached after 6 h of Ab exposure (Fig. 4a) while the protein levels were increased 18 h after treatment (Fig. 4b) . Exposure to 100 ng/mL VEGF for 18 h increased endothelial permeability to FITC-conjugated dextran (Fig. 4c) and significantly reduced expression of claudin-5 (Fig. 4d) . VEGF expression in astrocytes was reduced, using a short Fig. 2 Changes of claudin-5 expression are induced by Ab1-42 treatment only in endothelial astrocytes co-cultures. Endothelial cultures were exposed to Ab 2 lM for 18 h. The expression (a) and localization (b) of claudin-5 were evaluated by western blot and immunofluorescence analysis. Endothelial astrocytes co-cultures were exposed to Ab 2 lM for 18 h before western blot (c) and immunofluorescence analysis (d). Claudin-5 localization at the cytosolic (e) or membrane (f) compartment after Ab treatment was evaluated by western blot of proteins derived from subcellular fractionation. In the membrane compartment, the expression of flotillin was used as loading control. Values are expressed as percent of control. Data are mean AE SEM of 4 (a and c) and 6 (e and f) experiments. *p < 0.05 versus control. Significance was assessed by Student's t-test. In the histology panels white arrows show the areas in which claudin-5 localization at the boundaries is reduced, while asterisks indicate cytosolic translocation. Claudin-5 is represented in green, while 4 0 ,6-diamidino-2-phenylindole (DAPI) is used to counter-stain nuclei. Scale bar represents 10 lm interfering RNA (VEGF siRNA), yielding a marked downregulation of VEGF mRNA expression 24 h after transfection (Fig. 5a ). This effect was still maintained at 48 h when both RNA levels ( Fig. 5a ) and protein expression (Fig. 5b) were significantly reduced. Endothelial cells were therefore co-cultured with astrocytes expressing lower VEGF levels, and exposed to 2 lM Ab1-42 for further 18 h. After Ab challenge, endothelial permeability to FITC-conjugated dextran was significantly reduced when compared to co-cultures in which astrocytes were exposed to control siRNA Fig. 3 Conditioned media collected from Ab-treated astrocytes increase endothelial sensitivity to Ab. Endothelial cells were exposed to conditioned medium released by either resting [astrocyte conditioned medium (ACM resting)] or Ab1-42 (ACM Ab, 2 lM) challenged astrocytes. Endothelial permeability to FITC-conjugated dextran was evaluated (a). Endothelial monocultures were exposed to Ab1-42 (Ab, 2 lM) in the presence of either ACM resting (b) or ACM Ab (c). and endothelial permeability to FITC-conjugated dextran was evaluated after 30 min (b and c). Total claudin-5 expression was evaluated in endothelial cultures exposed to ACM resting or ACM Ab (d) and further challenged with Ab1-42 2 lM for 18 h (e). Panel f shows immunofluorescence of claudin-5 in endothelial cultures exposed to Ab in the presence of ACM Ab. Western blot analysis of claudin-5 in the cytosolic (g) and membrane (h) fractions of endothelial cultures exposed to Ab 1-42 in the presence of ACM Ab is reported in panels g and h. Monolayer permeability is expressed as percent of control of FITC-dextran-10 kDa fluorescent intensity. Values are expressed as percent of control. Data are mean AE SEM of 3 independent experiments. *p < 0.05 versus control. Significance was assessed by Student's t-test. In the images white arrows indicate the regions in which the protein localization at the boundaries was discontinued. Claudin-5 is represented in green, while 4 0 ,6-diamidino-2-phenylindole (DAPI) is used to counter-stain nuclei. Scale bar represents 10 lm.
(scramble) (Fig. 5c ). The expression of claudin-5 was evaluated in endothelial cells co-cultured with astrocytes expressing lower VEGF levels (siRNA VEGF); in this case, the expected reduction in claudin-5 expression after Ab challenge was not observed (Fig. 5d) . Immunocytochemistry analysis showed that the protein localization at the cell boundaries was still well defined after Ab challenge when endothelial cells were co-cultured with siRNA VEGF astrocytes (Fig. 5e ).
Astrocyte-mediated endothelial leakage requires MMP9
MMPs are known for their ability to induce TJ degradation. Their expression and activity were thus investigated in this model. MMP9 was significantly increased in endothelial cells co-cultured with astrocytes, after 18 h of exposure to 2 lM Ab1-42. MMP2 expression, in contrast, was only slightly but not significantly modified by the treatment (Fig. 6a) . However, when Ab1-42 was added directly to the endothelial monolayer, increased expression of MMP2, but not of MMP9, was observed (Fig. 6b) . Further, no modifications in the expression of MMP2 and MMP9 were observed in astrocytes exposed to Ab1-42 (Fig. S3 ). Since the co-culture model is the one in which we observed barrier modification after Ab exposure, we first analyzed MMP9 activity, in this condition, by gel zimography. The activity of MMP9 released in the media was significantly increased after Ab treatment (Fig. 6c) . In contrast, although a trend to an increase in MMP9 active form was observed, significance was not achieved when Ab was added directly to endothelial cultures (Fig. 6d) . However, when endothelial cells were exposed to Ab in the presence of ACM Ab, the expression of MMP9 in response to Ab insult was again mostly affected ( Fig. 6e-g ). Here Ab treatment induced in fact a significant up-regulation of MMP9 gene (Fig. 6e) and protein ( Fig. 6f ) expression and the enzymatic activity was increased as well (Fig. 6g ). MMP2 expression instead was not significantly affected, as indicated by gene expression, protein levels and enzymatic activity (Fig. S4) . Endothelial astrocytes co-cultures were then exposed to the broad spectrum MMP inhibitor GM6001 (5 lM) and challenged with Ab1-42 for 18 h. GM6001 was able to prevent both the enhanced permeability (Fig. 7a) and the reduced claudin-5 expression (Fig. 7b) induced by Ab1-42. Similarly, when endothelial cells were exposed to ACM Ab and treated with GM6001, the drug was able to prevent claudin-5 reduction induced by Ab insult (Ab+GM6001). The MMP inhibitor alone did not modify the expression of the protein (Fig. 7c) . Finally, the expression of MMP9 in endothelial cells co-cultured with siRNA VEGF astrocytes was investigated. Under these conditions, Ab-induced increase in MMP9 expression was prevented (Fig. 7d) .
Discussion
The BBB is a complex network in which endothelial properties are strongly affected by other components of the neurovascular unit (NVU). Pathological events may modify these interactions: in inflammatory conditions, for instance, astrocytes can affect endothelial properties by releasing cytokines (Nair et al. 2008) albeit they can also support BBB integrity (Mizee et al. 2014) . The role of astrocytes in neurodegeneration/neuroprotection in AD has been long debated too (Batarseh et al. 2016; Ries and Sastre 2016) , but their possible influence on BBB integrity has not been fully investigated. In our model, we wanted to evaluate whether endothelial barrier properties after Ab stimulation could be affected by the presence of astrocytes. Indeed, in our conditions, endothelial monolayer was not sensitive to Ab insult, albeit barrier leakage appeared when endothelial cells were exposed to Ab in the presence of astrocytes themselves or in the presence of ACM Ab. Previous studies have shown a direct effect of Ab on endothelial permeability and/or on TJ expression, but such effects were always observed in the presence of much higher Ab concentrations (up to 20 lM) (Marco and Skaper 2006; Tai et al. 2010; Gheorghiu et al. 2014) or in different in vitro models, like the retinal pigment epithelium (Park et al. 2014a) or choroid plexus epithelial cells (Brkic et al. 2015) . Alternatively, the effect of Ab (Ab1-42 oligomers, 10 lM) was associated with decreased endothelial cell viability (Wan et al. 2015) . At the low concentration we used, Ab was not able to induce either endothelial or astrocytes' death, but it presumably induced astrocytes to release soluble factor/s that could increase endothelial sensitivity to Ab itself. Our interpretation is supported by the observation that a similar effect by Ab was observed in the presence not only of astrocytes, but also of conditioned medium from Ab-pretreated astrocytes. The media released by Ab-challenged astrocytes, per se, did not induce endothelial damage: the properties of endothelial cells exposed to ACM Ab did not differ in fact from the condition in which they were exposed to ACM from resting astrocytes. An endothelial direct insult seems necessary to induce barrier properties modifications. Hence, astrocyte-released factor/s played a role in increasing endothelial sensitivity to Ab. Of note, disruption of membrane properties, either in the coculture system or in the presence of ACM Ab, was not only because of a redistribution of claudin-5 from the membrane to the cytosolic compartment, but also due to an overall reduction in claudin-5 expression. The two effects do not exclude each other and they seem to occur concomitantly. Modulation by astrocytes of endothelial response to Ab is not new. It has been shown, for instance, that the ability of Ab to down-regulate endothelial P-glycoprotein expression is reverted by astrocytes (Park et al. 2014b) . Also pericytes, the third component of the NVU, can modulate responses of endothelial cells, as shown by their attenuation of Abinduced changes of BBB properties (Park et al. 2016) , further strengthening the concept of a strict interaction among different cellular components at the BBB. Among soluble astrocytic factors able to modulate endothelial properties (Abbott et al. 2006) , one of the most interesting appeared VEGF that, besides its essential role in angiogenesis (Koch et al. 2011) , is released by reactive astrocytes upon inflammatory stimuli (Maharaj and D'Amore 2007; Argaw et al. 2012) and induces down-regulation of TJ protein expression thus causing barrier permeability (Chapouly et al. 2015) . In AD, VEGF is over-expressed in reactive astrocytes connected to blood vessels, via their endfeet, in proximity to perivascular Ab plaques (Thirumangalakudi et al. 2006; Dal et al. 2014) . Interestingly, Ab injection in animals caused VEGF immunoreactivity in astrocytes, but not in endothelial cells (Zand et al. 2005 ). In our model, we confirmed that Ab challenge, as previously suggested (Zand et al. 2005; Dal et al. 2014) , induces higher VEGF expression in astrocytes and identified VEGF as an essential factor in astrocyte/endothelium interplay. Under conditions of VEGF down-regulation, in fact, changes in barrier properties induced by Ab exposure, in terms of both permeability and TJ expression, were not observed anymore.
MMPs have been associated with VEGF effects as shown in in vivo and in vitro models (Valable et al. 2005; Hollborn et al. 2007) . Our attention was then focused on MMPs, as justified also by the fact that claudin-5 is a substrate for MMP2 and MMP9 (Fujimoto et al. 2008) . Accordingly, the involvement of MMPs in the degradation of TJs and the components of basal lamina has been demonstrated in several neurological conditions (Yang et al. 2007 (Yang et al. , 2013 Xin et al. 2012; Tasaki et al. 2014; Kim et al. 2015) . MMPs are implied in AD pathogenesis as well (Capaldo and Nusrat 2009) , and in particular their involvement in BBB damage has been proposed (Kook et al. 2012; Park et al. 2014b; Zenaro et al. 2016) . Furthermore, in vitro evidence supports MMP activities in TJ degradation induced by Ab both at the BBB (Wan et al. 2015) and at the blood-cerebrospinal fluid barrier (Brkic et al. 2015) .
We observed an increased expression of MMP9 following Ab challenge only when endothelial cells were exposed to astrocytes, either in co-culture or after conditioned medium transfer. MMP9 enzymatic activity was then assessed in released medium by gel zymography. Data obtained confirmed that increased MPP9 activity in endothelial cells was related to the influence of astrocytes. These data apparently contrast with recent findings demonstrating a direct effect of Ab on the expression and activity of both MMP2 and MMP9 directly in endothelial cells. However, again, only isolated oligomers of Ab1-42 were used in that study and this can justify this discrepancy (Wan et al. 2015) . In addition, we could detect a slight increase in MMP2 expression when endothelial cells were directly exposed to Ab, an effect that cannot be excluded to occur, under appropriate conditions. Modifications in barrier properties were prevented when the non-specific MMP inhibitor, GM6001, was added to the astrocyte-endothelium co-culture. However, to dissect the cellular source of MMP mediating this effect, GM6001 was added only to endothelial cells exposed to Ab in the presence of ACM Ab. When added in the presence of ACM Ab, the MMPs inhibitor did not modify basal expression of claudin-5, while it prevented the expected reduction in the protein induced by Ab treatment, pointing out the central role played by endothelial MMPs in this effect. As known, inhibition by GM6001 is not selective and an involvement of MMP2 or other MMPs cannot be ruled out. Interestingly, i.c.v. injection of Ab1-42 oligomers produced, in choroid plexus epithelial cells, increased expression of several MMPs, including MMP9, likely responsible for loss of blood-CSF barrier integrity (Brkic et al. 2015) . Enhanced leakage was prevented by the broad spectrum MMP inhibitor, but also in MMP3 À/À deficient mice, suggesting a prominent role, specifically for MMP3, in Ab1-42 oligomers-induced damage at the blood-CSF barrier (Brkic et al. 2015) . Very recently, a major role in BBB microvascular hyperpermeability has been instead recognized to MMP9, as shown by prevention of BBB disruption under conditions of MMP9 inhibition by pharmacological or molecular tools, in vitro and in vivo (Alluri et al. 2016) .
In order to find a link between astrocyte-derived VEGF and MMP9 activation, with ensuing enhanced endothelium permeability, the same experiments were performed under conditions of VEGF down-regulation in astrocytes. This caused prevention of Ab effects on MMP9 expression and barrier properties, reinforcing the concept that VEGF represents the, or one of the, critical factor/s mediating astrocyte/ endothelial cells interplay in this protocol.
The importance of the interplay between the different components of the NVU cannot be denied. In physiological conditions astrocytes strongly affect endothelial properties, thus reinforcing BBB. However, also in pathological conditions, as we observed in our system, astrocytes/endothelial communication influences barrier functions. The involvement of astrocytes, important to induce endothelial sensitivity to low Ab challenge, is likely to occur in a more complex in vivo system, in which Ab accumulation in the CNS can modify astroglial activity; these events lead to increased BBB damage that eventually may induce the infiltration of molecules and immune cells that participate to neuronal degeneration in AD. Astrocytes modifications induced by endothelial cells, on the other hand, cannot be excluded, further pointing out that the NVU is a complex network in which the interaction of all the components affects their response to physiological and pathological stimuli.
In conclusion, our results demonstrate that astrocytes are primarily involved in the toxic effects of Ab at the BBB. A detailed knowledge of factors of astrocytic origin and pathways activated at the endothelial level as mediators of this cellular interplay, may help to identify new targets for prevention of Ab-induced BBB damage.
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Additional Supporting Information may be found online in the supporting information tab for this article: Figure S1 . Modification in endothelial permeability induced by Ab treatment. Endothelial cultures were exposed to Ab1-42 (Ab) 2 lM for 18 h. Endothelial properties were evaluated measuring FITC-conjugated dextran permeability through the monolayer, 60 and 120 min after addition of the dye (a and b). Endothelial cells were co-cultured with astrocytes and exposed to Ab 2 lM for 18 h before permeability assay was performed; dextran permeability through the insert was evaluated 60 and 120 min after addition of the dye (c and d). Monolayer permeability is expressed as percentage of control of FITC-dextran-10 kDa fluorescent intensity. Values represent mean AE SEM of 3-4 independent experiments.*p < 0.05 versus control. Significance was assessed by Student's t test. Figure S2 . Concentration response curve of Ab on endothelial and astrocytes viability. Astrocytes (a) and endothelial cells (b) were exposed to increasing concentrations of Ab 1-42 (0.5, 2, 5 lM) for 24 h. MTT assay was performed to evaluate cell viability. The concentration of 2 lM was not able to modify either endothelial or astrocytes viability and was used for all the described experiments., *p < 0.05 versus control. Significance was assessed by one-way ANOVA and Newman-Keuls test. Figure S3 . Ab treatment did not modify the expression of MMP2 and -9 in astrocytes. Astrocytes were exposed to Ab1-42 (Ab, 2 lM) for 18 h. The expression of both MMP9 (a) and MMP2 (b), was evaluated. The treatment was not able to induce modifications in the expression of the protein. Data are mean AE SEM of 3 experiments Significance was assessed by Student's t test. Figure S4 . Ab treatment did not modify the expression and the activity of MMP2 in endothelial cells. Both endothelial-astrocytes co-cultures and endothelial monolayers were exposed to Ab 2 lM for 18 h. The medium released by endothelial cells following exposure to Ab either in the presence of astrocytes (a) or in monoculture (b) was subjected to gelatin zymography assay to evaluate MMP2 enzymatic activity. No modification in the activity of the gelatinase was observed. In c (qRT-PCR) and d (western blot) expression of MMP2 in endothelial cells exposed to Ab 2 lM in the presence of ACM Ab, is shown. The release and activity of the protease was evaluated by processing endothelial culture media in a gelatin zymography assay (e). Values are expressed as percent of control. Data are mean AE SEM of 3 experiments. Significance was assessed by Student's t-test.
